var data={"title":"Factor IX, human plasma-derived: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor IX, human plasma-derived: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/541150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-ix-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor IX, human plasma-derived: Patient drug information&quot;</a> and <a href=\"topic.htm?path=factor-ix-human-plasma-derived-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor IX, human plasma-derived: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264034\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AlphaNine SD;</li>\n      <li>Mononine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264035\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Immunine VH</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264038\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321187\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: <i>AlphaNine SD, Mononine: </i>Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Formula to determine units required to obtain desired factor IX level:</i></b> <b>Note:</b> If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1 unit/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For example, to attain an 80% level in a 70 kg patient who has a baseline level of 20%: Number of factor IX units needed = 70 kg x 60% x 1 unit/kg = 4200 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Alternative dosing (off-label): Note:</b> The following recommendations may vary from those found within prescribing information or practitioner preference.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> 15 to 30 units/kg/dose twice weekly (Utrecht protocol; WFH [Srivastava 2013]) <b>or</b> 25 to 40 units/kg/dose twice weekly (Malm&ouml; protocol; WFH [Srivastava 2013]); optimum regimen has yet to be defined.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists):</caption>\n      <col></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th>\n            <p style=\"text-indent:0em;\">Site of Hemorrhage/Clinical Situation</p></th>\n          <th>\n            <p style=\"text-indent:0em;\">Desired Factor IX Level to Maintain</p></th>\n          <th>\n            <p style=\"text-indent:0em;\">Duration</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:0em;\">\n              <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Joint</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">1 to 2 days, may be longer if response is inadequate</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Superficial muscle/no neurovascular compromise</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 to 60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60 to 80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 to 60 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 2 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>CNS/head</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60 to 80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 21 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Throat and neck</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60 to 80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 1 to 7 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 8 to 14 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Gastrointestinal</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 60 to 80 units/dL</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> 30 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Initial:</i> 7 to 14 days</p>\n            <p style=\"text-indent:0em;\">\n              <i>Maintenance:</i> Not specified</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Renal</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">3 to 5 days</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <b>Deep laceration</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">5 to 7 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\">\n            <p style=\"text-indent:0em;\">\n              <b>Surgery (major)</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 60 to 80 units/dL</p></td>\n          <td></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i></p>\n            <p style=\"text-indent:0em;margin-left:2em;\">40 to 60 units/dL</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">30 to 50 units/dL</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">20 to 40 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i></p>\n            <p style=\"text-indent:0em;margin-left:2em;\">1 to 3 days</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">4 to 6 days</p>\n            <p style=\"text-indent:0em;margin-left:2em;\">7 to 14 days</p></td></tr>\n        <tr>\n          <td rowspan=\"2\">\n            <p style=\"text-indent:0em;\">\n              <b>Surgery (minor)</b></p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Preop:</i> 50 to 80 units/dL</p></td>\n          <td></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 30 to 80 units/dL</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">\n              <i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Continuous infusion (for patients who require prolonged periods of treatment [eg, intracranial hemorrhage or surgery] to avoid peaks and troughs associated with intermittent infusions) (Batorova, 2002; Poon, 2012; Rickard, 1995; WFH [Srivastava 2013]):</i> Following initial bolus to achieve the desired factor IX level: Initiate 4 to 6 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor IX clearance at steady-state using the following equations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (plasma level in units/<b>m</b>L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>m</b>L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16318994\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-human-plasma-derived-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor IX, human plasma-derived: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> Infants, Children, and Adolescents: IV: <i>AlphaNine SD, Mononine: </i>Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Formula to determine units required to obtain desired factor IX level:</i></b> <b>Note:</b> If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1 unit/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For example, to attain an 80% level in a 70 kg patient who has a baseline level of 20%: Number of factor IX units needed = 70 kg x 60% x 1 unit/kg = 4200 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Alternative recommendations (off-label):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis, primary: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16318995\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321198\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 500 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 500 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1000 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1000 units (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlphaNine SD: 1500 units (1 ea) [contains heparin, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mononine: 250 units (1 ea [DSC]); 500 units (1 ea [DSC]); 1000 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573583\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321188\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: IV administration only: Should be infused <b>slowly over several minutes</b>: Rate of administration should be determined by the response and comfort of the patient. Solution should be infused at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AlphaNine SD: Administer IV at a rate not exceeding 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mononine: Administer IV at a rate of ~2 mL/minute. Administration rates of up to 225 <b>units</b>/minute have been regularly tolerated without incident (when reconstituted as directed to ~100 units/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">World Federation of Hemophilia recommendations: Infuse by slow IV injection at a rate not to exceed 3 mL/minute (adults) or 100 <b>units</b>/minute (young children); may also administer as a continuous infusion in select patients. With patients who have anti-factor IX inhibitors who have had allergic reactions during factor IX infusion, administration of hydrocortisone prior to infusion may be necessary (WFH [Srivastava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264042\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention and control of bleeding in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>NOTE:</b> Contains <b>nondetectable levels of factors II, VII, and X</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264032\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Factor IX may be confused with Factor IX Complex </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265557\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Burning sensation (in jaw/skull), chills, headache, lethargy, paresthesia, rigors </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin photosensitivity, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Discomfort at injection site (stinging, burning), injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Neck tightness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Allergic rhinitis, asthma, laryngeal edema, pulmonary disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (including transient fever following rapid administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Angioedema, cerebral hemorrhage (intrathalamic [Douvas, 2004]), cyanosis, decreased therapeutic response, dyspnea, factor IX inhibitor development, hypotension, myocardial infarction (high doses), pulmonary embolism (high doses), superior vena cava syndrome (neonates [Douvas, 2004])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264049\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AlphaNine SD: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mononine: Hypersensitivity to mouse protein</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264050\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava  2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions may be associated with factor IX inhibitor development; patients experiencing allergic reactions should be evaluated for factor IX inhibitors (WFH [Srivastava  2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Observe closely for signs or symptoms of intravascular coagulation or thrombosis; risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX). Use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, disseminated intravascular coagulation or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the risk of thromboembolic complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma. Despite purification methods (AlphaNine SD - solvent detergent treated/virus filtered; Mononine - virus filtered); products may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Contains <b>nondetectable levels of factors II, VII, and X.</b> Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX. In addition, factor IX concentrate is <b>NOT INDICATED </b>for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), hemophilia A patients with factor VIII inhibitors, or patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune tolerance induction: Safety and efficacy have not been established in immune tolerance induction with factor IX products. Nephrotic syndrome has occurred following immune tolerance induction in patients with factor IX inhibitors and a history of allergic reactions to therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369064\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369062\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88578&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16264048\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor IX concentrations do not change significantly in pregnant women with coagulation disorders and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Chi, 2012; Kadir, 2009; Lee, 2006). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321190\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Factor IX levels (measure 15 minutes after infusion to verify calculated doses) (WFH [Srivastava], 2013), aPTT, BP, HR, signs of hypersensitivity reactions; screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals (WFH [Srivastava], 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21 to 50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults (with &gt;150 exposure days apart from a 6 to 12 monthly review): Screen for inhibitors when suboptimal response occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265653\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Average normal factor IX levels are 50% to 150%; patients with severe hemophilia B will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265581\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265654\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: IX component: ~21 to 25 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570473\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AlphaNine SD Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mononine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.61</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aimafix (TH);</li>\n      <li>Alphanine SD (AE, HK, SG, TH, TW);</li>\n      <li>Bebulin Team 4 (RU);</li>\n      <li>Berinin P (CO);</li>\n      <li>Betafact (IL, LB);</li>\n      <li>Facnyne (KR);</li>\n      <li>Haemonine (GB);</li>\n      <li>Haemosolvex (ZA);</li>\n      <li>Immunine (DE, EE, KW, SE, TH);</li>\n      <li>MonoFIX-VF (AU, NZ);</li>\n      <li>Mononine (CZ, DE, ES, FR, GB, GR, IE, NL, SE, SI, SK);</li>\n      <li>Nonafact (AT, BE, BG, CZ, DK, EE, GR, HR, HU, IE, IT, LT, MT, NL, PL, RO, RU, SE, SK, TR);</li>\n      <li>Octafix (FR);</li>\n      <li>Octanine (MY);</li>\n      <li>Octanine F (AE, CR, DO, GT, HN, NI, PA, SA, SV, UY);</li>\n      <li>Profilnine SD (AE, MY, PH, SG, TH);</li>\n      <li>Replenine VF (IL, MY);</li>\n      <li>Replenine-VF (KW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AlphaNine (factor IX [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A and Martinowitz U, &quot;Continuous Infusion of Coagulation Factors,&quot; <i>Haemophilia</i>, 2002, 8(3):170-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/12010406/pubmed\" target=\"_blank\" id=\"12010406\">12010406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi C and Kadir RA, &quot;Inherited Bleeding Disorders in Pregnancy,&quot; <i>Best Pract Res Clin Obstet Gynaecol</i>, 2012, 26(1):103-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/22101176/pubmed\" target=\"_blank\" id=\"22101176\">22101176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douvas MG, Monahan PE. Life-threatening thrombosis complicating the management of hepatic hemorrhage: anticoagulant treatment in a newborn with hemophilia B. <i>J Pediatr Hematol Oncol. 2004;26(4):258-263.</i><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/15087956/pubmed\" target=\"_blank\" id=\"15087956\">15087956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, and Bolton-Maggs P, &quot;Pregnancy and Rare Bleeding Disorders,&quot; <i>Haemophilia</i>, 2009, 15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al, &quot;The Obstetric and Gynaecological Management of Women With Inherited Bleeding Disorders-Review With Guidelines Produced by a Taskforce of UK Haemophilia Centre Doctors' Organization,&quot; <i>Haemophilia</i>, 2006, 12(4):301-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mononine (coagulation factor ix human) [prescribing information]. Kankakee, IL: CSL Behring LLC; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC and Card R, &quot;Hemophilia Management in Transfusion Medicine,&quot; <i>Transfus Apher Sci</i>, 2012, 46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rickard KA, &ldquo;Guidelines for Therapy and Optimal Dosages of Coagulation Factors for Treatment of Bleeding and Surgery in Haemophilia,&rdquo; <i>Haemophilia</i>, 1995, 1(suppl 1):8-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shibata M, Shima M, Misu H, et al, &quot;Management of Haemophilia B Inhibitor Patients With Anaphylactic Reactions to FIX Concentrates,&quot; <i>Haemophilia</i>, 2003, 9(3):269-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/12694516/pubmed\" target=\"_blank\" id=\"12694516\">12694516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shord SS and Lindley CM, &quot;Coagulation Products and Their Uses,&quot; <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/10938981/pubmed\" target=\"_blank\" id=\"10938981\">10938981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al, on behalf of the World Federation of Hemophilia (WFH), &quot;Guidelines for the Management of Hemophilia,&quot; Haemophilia, 2013, 19(1):e1-47. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2012.02909.x/pdf22776238</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, &quot;Dose and Response in Haemophilia--Optimization of Factor Replacement Therapy,&quot; <i>Br J Haematol</i>, 2004, 127(1):12-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/15384973/pubmed\" target=\"_blank\" id=\"15384973\">15384973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varon D and Martinowitz U, &quot;Continuous Infusion Therapy in Haemophilia,&quot; <i>Haemophilia</i>, 1998, 4(4):431-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/9873771/pubmed\" target=\"_blank\" id=\"9873771\">9873771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White GC 2nd, Beebe A, and Nielsen B, &quot;Recombinant Factor IX,&quot; <i>Thromb Haemost</i>, 1997, 78(1):261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-human-plasma-derived-drug-information/abstract-text/9198163/pubmed\" target=\"_blank\" id=\"9198163\">9198163</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88578 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16264034\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16264035\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16264038\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16321187\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F16318994\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16318995\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16321198\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16264037\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573583\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16321188\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16264042\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16264032\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16265557\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16264049\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16264050\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369064\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369062\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16264047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16264048\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16321190\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F16265653\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16265581\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16265654\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570473\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88578|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-ix-human-plasma-derived-patient-drug-information\" class=\"drug drug_patient\">Factor IX, human plasma-derived: Patient drug information</a></li><li><a href=\"topic.htm?path=factor-ix-human-plasma-derived-pediatric-drug-information\" class=\"drug drug_pediatric\">Factor IX, human plasma-derived: Pediatric drug information</a></li></ul></div></div>","javascript":null}